Podcasts about CRISPR

If a species is horrible enough, do we have the right to kill it forever? Seventy years ago, a nightmare parasite feasted on the live flesh of warm-blooded creatures in North America: the screwworm. That is, until a young scientist named Edward F. Knipling discovered a crucial screwworm weakness and hatched a sweeping project to wipe them out. Knipling's seemingly zany plan to spray screwworms out of planes all over the continent— with US taxpayer money— succeeded, becoming one of humanity's biggest environmental interventions ever.  Today, screwworms have been gone so long that none of us in North America even remember them. But now, they're coming back. And they're forcing us to ask: in an era of climate change and rapid mass extinction— should we kill off a species on purpose?  Special thanks to James P. Collins, Max Scott, Amy Murillo, Daniel Griffin, Phil Kaufman, Katie Barnhill, Arthur Caplan, Ron Sandler, Yasha Rohwer, Aaron Keefe, Gwendolyn Bogard, Maria Sabate, Meredith Asbury, and Joanne Padrón CarneyEPISODE CREDITS:  Reported by - Sarah Qari with help from - Latif Nasser Produced by - Sarah Qari Sound design contributed by - Sarah Qari Fact-checking by - Emily Krieger EPISODE CITATIONS: **The latest information on screwworm outbreaks and precautions: screwworm.gov Videos: Oral history interviews of Edward F. Knipling: here (https://zpr.io/njhMedFN5jsZ) and here (https://zpr.io/VQReQbfznCrq)  Podcasts: Here's a Spotify playlist (https://zpr.io/PNMEM274G7vh)  of all of our Golden Goose-inspired episodes! Sam Kean's podcast The Disappearing Spoon – his episode about screwworms is called The Screwiest and Perhaps Most Original Idea of the 20th Century (https://zpr.io/UYf6dR2yG3eN)  Our episode on CRISPR & gene drives (https://zpr.io/UYf6dR2yG3eN)  New to Radiolab? Check out our Radiolab Starter Kit (https://zpr.io/QpPnrHAZVQLR)  playlist of all-time favorite episodes! Articles: Sarah Zhang's latest piece in The Atlantic: American Milk Has Changed (https://zpr.io/xebbdq2MWV4L)  Her most recent piece on screwworms: The ‘Man-Eater' Screwworm Is Coming (https://zpr.io/ECmjCs7ScbS4)  Her initial reporting on screwworms: America's Never-Ending Battle Against Flesh-Eating Worms (https://zpr.io/PNMEM274G7vh)  Gregory Kaebnick's paper (https://zpr.io/yqNC3q5FbCcq)  about screwworm eradication in Science Archival materials:  The USDA's Screwworm Eradication Records (https://zpr.io/dY7zuVdGYKjf) contain lots of cool images and letters Signup for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Sign up (https://radiolab.org/newsletter)! Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today. Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org. Leadership support for Radiolab's science programming is provided by the Simons Foundation and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.

Dr. Alex Marson, MD, PhD, is a professor of medicine at the University of California, San Francisco. We discuss the biology of the immune system and cancer, and everyday choices that can increase or decrease your cancer risk, several of which are surprising but all of which are actionable. We also discuss immunotherapy, including how engineered T-cells can be used to defeat childhood and adult cancers. Dr. Marson explains CRISPR and gene editing to cure diseases, and we address the ethical questions surrounding gene editing in embryos, children and adults. This discussion is for anyone interested in avoiding cancer and/or seeking to understand the science and practical applications of immune- or gene-therapy. Read the show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman BetterHelp: https://betterhelp.com/huberman Helix Sleep: https://helixsleep.com/huberman LMNT: https://drinklmnt.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00:00) Alex Marson (00:02:21) Diseases & Current Biological Landscape; AI & Computational Tools (00:05:56) Immune System, Innate vs Adaptive Immune System (00:10:55) Thymus, T Cell Selection; B Cells & Antibodies (00:13:23) Sponsors: BetterHelp & Helix Sleep (00:16:11) Immune System Health, Sleep, Diet; Genes (00:20:56) Childhood Exposure & Allergy Prevention; Autoimmune Reactions (00:25:27) Whole Body Immune Response, Cytokines & Fever; Antibiotics (00:30:51) Cancer; Mutations & Cell Regulation; Smoking, BRCA Mutations, Sunlight (00:38:27) BRAC Mutations, Mutagens, Pesticides (00:42:33) Sponsor: AG1 (00:43:57) X-Rays & Airport Scanners, Carcinogen vs Mutagen, Charred Meat, Food Dye (00:49:34) Immune-Based Cancer Treatment, Checkpoint Inhibitors, CAR T-Cell Therapy (00:59:04) CRISPR, Immunotherapies (01:02:52) Age & Cancer Risk; CAR T-Cells, Targets & Side Effects; Ketogenic Diet (01:08:27) CRISPR Discovery & Mechanism (01:17:06) CRISPR Precision, Risk & Benefit; CRISPR Technology Evolution (01:20:57) Sponsor: LMNT (01:22:17) CRISPR Cell Delivery, Clinical Trials; Treating Early Cancers & Prevention (01:33:47) Liposomes, Engineered Viruses, Lipid Nanoparticles (LNPs), Vaccines (01:39:57) COVID Pandemic & Trust in Science, mRNA Vaccine (01:47:51) Sponsor: Function (01:49:39) Drug Delivery to Cancer, Immunotoxins, T-Cell Engagers; AI Protein Targets (01:55:45) CRISPR Embryo Modification, Ethics; Heritable Gene Editing, Diversity (02:05:42) Deep Sequencing Embryos, Diversity; Overcoming Adversity & Resilience (02:10:44) Upcoming Therapeutics, Autoimmunity & CAR T-Cells, CRISPR & Gene Function (02:17:55) Banking T Cells or iPSCs?, Future of Cell Programming (02:24:41) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and trends shaping the industry landscape, offering insight into the dynamic interplay between scientific innovation, regulatory challenges, and strategic growth.Starting with the recent departure of Vinay Prasad from the U.S. Food and Drug Administration, particularly from his role as director of the Center for Biologics Evaluation and Research (CBER). Prasad's tenure, though brief, left an indelible mark characterized by controversy and debate over regulatory decisions. His leadership coincided with significant advancements in biologics and gene editing technologies, like CRISPR, highlighting the complexities in balancing innovation with safety standards. Under Prasad's guidance, the FDA faced challenges in navigating these rapid advancements while maintaining rigorous oversight to ensure that new therapies are both effective and safe for public use. Prasad's resignation signals potential shifts in regulatory philosophy at CBER. The biotech industry is watching closely to see how new leadership will influence ongoing and future evaluations of biologics. The change presents an opportunity to reassess how regulatory bodies can better adapt to scientific advancements while ensuring that patient safety remains paramount. The issues faced during Prasad's tenure underscore the need for transparent decision-making and open communication with stakeholders, which are vital for maintaining trust in regulatory processes.Meanwhile, Pfizer has made a strategic entry into the Chinese obesity market with the approval of a GLP-1 drug developed alongside Sciwind Biosciences. This approval represents not only a significant step for Pfizer but also underscores a broader global focus on obesity management. The efficacy of GLP-1 receptor agonists in weight regulation has opened up new market opportunities, highlighting the growing importance of metabolic health solutions in addressing public health challenges.In other news, Johnson & Johnson's Tecvayli-Darzalex combination therapy has received its third national priority recognition from the FDA for treating multiple myeloma. This recognition reflects promising Phase 3 trial results and underscores the critical role of innovative combination therapies in improving outcomes for complex hematologic malignancies. The success of such therapies illustrates how targeted approaches can significantly enhance treatment efficacy and patient quality of life.Strategic acquisitions continue to reshape industry dynamics. Servier's $2.5 billion acquisition of Day One Biopharmaceuticals aims to strengthen its rare cancer portfolio, including a promising glioma drug, Ojemda. This move highlights Servier's commitment to addressing unmet needs in pediatric oncology and rare diseases, emphasizing a broader industry trend towards focusing on niche therapeutic areas with high potential impact.Regulatory activities are gaining momentum as well, with the FDA set to end a nine-month hiatus in advisory committee meetings by reviewing AstraZeneca's oral selective estrogen receptor degrader Truqa. As AstraZeneca seeks to enhance its oncology pipeline, this review signals ongoing innovation in hormone-based cancer therapies and reflects a renewed emphasis on bringing novel treatments to market efficiently.Additionally, Glenmark Pharmaceuticals has achieved a significant milestone with FDA approval for its generic version of GSK's asthma inhaler Flovent. This development exemplifies efforts to improve access to respiratory treatments by providing cost-effective alternatives to branded medications, potentially reducing healthcare costs while enhancing patient access.On an international scale, Taiwan has announced a substantial investment plan aimed at bolstering its drugSupport the show

Conserved neuropeptide Y GPCRs orchestrate both feeding and mating behaviors in mosquitoes, with direct translational parallels to human gut-brain signaling.Quick SummaryLearn how receptor internalization and neuropeptide GPCR signaling underlie the regulation of mosquito host-seeking and reproduction. Dr. Laura Duvall details the use of CRISPR-based assay development and fluorescence-driven phenotyping to connect molecular manipulation to whole-animal behavior. Her approach provides actionable insights for gpcr drug discovery and tools to dissect homologous pathways across model systems, with implications for pharmacology research targeting vector-borne disease transmission.Key TakeawaysNeuropeptide Y GPCRs modulate both host attraction and mating in Aedes aegypti.CRISPR and fluorescence assays enable precise behavioral phenotyping in vivo.GPCR-targeted compounds designed for humans can modulate mosquito receptors.NPY receptor expression in mosquito gut mirrors mammalian gut-brain signaling axes.Automated behavioral assays combined with machine learning sharpen data resolution and reduce human bias.Dr. GPCR Links & ResourcesExplore essential resources:Dr. GPCR EcosystemMembership & PricingWeekly NewsAdvance your research—discover the power of Dr. GPCR Premium.About the GuestDr. Laura Duvall earned her B.A. in Biochemistry and Biological Basis of Behavior from the University of Pennsylvania, followed by a PhD at Washington University in St. Louis, where she explored neuropeptide regulation of circadian behavior in Drosophila. Transitioning from fruit flies to mosquitoes, she pursued postdoctoral research at Rockefeller University with Leslie Vosshall, focusing on the molecular regulation of feeding and mating behaviors in Aedes aegypti. In 2019, she established her independent laboratory at Columbia University's Department of Biological Sciences and the Zuckerman Institute. Dr. Duvall's work is recognized by awards including the Beckman Young Investigator Award, Klingenstein-Simons Fellowship in Neuroscience, and the Pew Scholars Program, reflecting her drive to unravel the complex signaling mechanisms that govern mosquito and broader animal behavior.Guest on The WebLinkedIn: https://www.linkedin.com/in/laura-duvall-28a03485/Google Scholar: https://scholar.google.com/citations?user=Vk3KGSoAAAAJ&hl=enLab: https://www.duvalllab.com/

​Episode 2 of ongoing research on Tuberous Sclerosis Complex based on the query~Is CRISPR CAS9 being researched to help/cure tuberous sclerosis?"An exchange with Google AI mode in reference to the above query with the intention of making it clear the trajectory for those with rare diseases in terms of overriding our biological organic template and moving towards a more synthetic version. I picked up where I left off with Episode 1 and talk through Epigenetic "Switches", Gut-Brain Axis and Neuroinflammation, Why Researchers Are Skipping These Links, Potential Reasons for the Research Focus, Funding and Corporate Partnerships, Neuroinflammation Research, The "TAND" Project (TSC-Associated Neuropsychiatric Disorders), The PREVENT Trial, Basic Science and "Somatic Mosaicism", The "Funding Gap" regarding Conflicts of Interest, The Logic of the "Omission", Lived Experience vs. "Proven" Science,Why It Feels "Diabolical" & Finding the "Clean" Data https://www.mdpi.com/1422-0067/22/14/7273 https://pmc.ncbi.nlm.nih.gov/articles/PMC11275973/ https://www.ncbi.nlm.nih.gov/books/NBK206940/ https://www.nature.com/articles/s41398-024-02752-y https://clinicaltrials.gov/study/NCT01289912 https://pmc.ncbi.nlm.nih.gov/articles/PMC9253752/ https://www.intechopen.com/chapters/82669 https://pmc.ncbi.nlm.nih.gov/articles/PMC6748183/ https://pmc.ncbi.nlm.nih.gov/articles/PMC6278824/ https://www.nature.com/articles/s41439-022-00181-1 https://pmc.ncbi.nlm.nih.gov/articles/PMC3035853/ https://pmc.ncbi.nlm.nih.gov/articles/PMC5804531/ https://pubmed.ncbi.nlm.nih.gov/40558831/ https://docs.google.com/document/d/1ncDHvfDHkzVd1-H4Xgulz-mhSZxhwhydK6jWln90L5E/ (contact pjlacy6@gmail.com for access)Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

This month in looking at what's going on in the world we look at the next push for gene editing, AI hiring humans to do their "meatspace" tasks, a curious connection with Epstein and 9/11. UFO's and several other topics are discussed on today's episode!Email us at: downtherh@protonmail.com

"Is CRISPR CAS9 being researched to help/cure tuberous sclerosis?" An exchange with Google AI mode in reference to the above query with the intention of making it clear the trajectory for those with rare diseases in terms of overriding our biological organic template and moving towards a more synthetic version. For many this will bring great relief as these rare diseases are challenging for affected and the ripple created in the realm. Instead of considering ALL the factors that have exacerbated and amplified rare diseases to the point of no return, our powers that be are forging ahead with gene therapy, at the germline. This disease is a data generator, and the affected population a perfect test template for gathering the intel needed , organ by organ to duplicate and integrate with the tech. No judgement, just sharing the conversation as I feel it's important to share these exchanges with the body of knowledge currently feeding the AI. https://youtu.be/lZKqFZWnp0c Here's a link to the queries. https://share.google/aimode/mwKaYPnKgzw54cs76Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

In this episode of 10X Growth Strategies, host Arthi Vijayaraghavan sits down with Lakshmi Nair — drug development scientist and genetic engineering researcher — to unpack the science, promise, and responsibility behind CRISPR and gene editing. Drawing from her journey across academia and biomedical research, Lakshmi explains how CRISPR transformed genetic engineering from slow, uncertain experimentation into precise DNA editing — and why that leap could reshape medicine, cancer treatment, and hereditary disease forever. From transgenic models and drug development to the realities of scientific failure and perseverance, the conversation reveals what modern biomedical innovation truly looks like behind the scenes. The episode explores the ethical frontier of gene editing — germline modification, designer traits, disability vs identity, and who gets to decide what should be “fixed” in humans. The discussion also connects CRISPR with AI-driven research, data-intensive clinical trials, and the global scientific ecosystem that turns basic research into life-saving therapies. From biohacking and scientific curiosity to regulation, responsibility, and the future of humanity, this is a thoughtful, deeply grounded conversation on what it means to hold the power to rewrite life itself. A fascinating listen for technologists, policymakers, investors, and anyone curious about where biology, AI, and human evolution intersect. ⸻ 00:00 – Introduction & Lakshmi's Background 02:00 – Why CRISPR Changed Genetic Engineering 06:00 – Scientific Journeys, Curiosity & Upbringing 12:00 – CRISPR Explained for Non-Biologists 18:30 – Medical Applications: Cancer & Genetic Disease 23:30 – Scientific Collaboration & Peer Review 26:30 – Biohacking & Democratizing Biology 30:00 – Gene Editing Ethics & Germline Debate 36:00 – Identity, Disability & Human Choice 40:00 – From Lab Research to Drug Development 45:00 – AI in Clinical Trials & Biomedical Data 50:00 – Future of Gene Editing & Responsibility 54:00 – Closing Reflections

This interview of Alex Newman, the founder and CEO of Liberty Sentinel Media, by Ginger and Peter Breggin focuses on the newly released “million of Epstein pages” by the Trump Administration. Newman has been studying Epstein for many years, especially in light of his multiple globalist connections, including his support from America's Deep State bureaucracy. Alex Newman analyses newly released pages from the Epstein files concerning Epstein's work to further globalist ambitions for transhumanistic projects at Harvard and other universities, including using recently developed CRISPR technology to produce genetically modified human beings. We discuss the relationship between the evil psychology underpinning globalism, imperialism, and transhumanism, and how it poses a threat to all of Western civilization, including its goal to annihilate Christianity. The three of us discuss not only these mind-bending issues but also our own psychological and emotional blocks to even thinking about or writing about them, especially the existence of such horrendously evil intentions motivating many of the most powerful and influential people on Earth.

Pairwise: https://www.pairwise.com/FoA 412: 'Biological' Is Not A Category (it's the future of agriculture)I'm excited to share today's episode with you. I've wanted to get Tom Adams back on the show ever since I had the chance to interview him at World Agritech a couple of years ago. That interview was included on episode 412 of this podcast titled “Biological is not a Category”. The work Pairwise is doing is mind boggling to me. Using CRISPR and the latest in gene editing tools, they have built a platform to enable plant breeders to make very precise changes to the genome of a plant to give farmers and consumers more of what they want. Now this is different from genetic modification or GMOs because they are not inserting foreign genes into the plant. In fact, they are doing the exact same thing that plant breeders have done for over a century, they are just able to do it in an extremely precise way. On another podcast that I host, Agriscience Explained, Corteva's Reza Rasoulpour explained natural breeding as wanting to change one word in a book by just combining all of the pages of two different books and hoping that word changes. Versus gene editing just going in and changing that one word in the book. I thought that was a good comparison. So Tom and his team are bringing this technology to agriculture by working with seed companies and other partners in a variety of use cases, many of which we'll discuss today. A little background on Tom: Dr. Tom Adams co-founded Pairwise and serves as Chief Executive Officer. Tom has over 25 years of leadership experience heading up biotechnology for global companies, serving most recently as Vice President of Global Biotechnology at Monsanto where he led the team developing a broad range of innovative products. Tom wanted to realize the possibilities of CRISPR and gene editing in plants, and co-founded Pairwise to realize this potential in a mission-based environment. Formerly a faculty member at Texas A&M University, Tom holds a PhD in microbiology and plant science from Michigan State University and a BS in botany and plant pathology from Oregon State University. Tom and I talk about Pairwise's continued work in this area, some of the cool developments that are under way, some of their strategic decisions like going the partnership route rather than being the seed company themselves, a little bit more about how the technology works, how this changes the game and who captures the value.

Crispr's ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer Jennifer Doudna wants to build an entire ecosystem to bring these treatments mainstream. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, he and Niklas explore how genome sequencing, DNA synthesis, and CRISPR are turning life into an engineering platform. From coding proteins and viruses to writing entire genomes, Andrew explains how biotech is moving from reading DNA to actively programming it.They discuss N-of-1 personalized therapies, biosecurity in an age of cheap DNA synthesis, and why open science could accelerate biotech innovation. The conversation also touches on cloning, embryo editing, and the long-term future of human enhancement.Topics include:· DNA as digital code · Genome writing and synthetic cells · CRISPR and programmable biology · Personalized genetic medicine · Biosecurity and engineered viruses · Open biotech vs. proprietary models · Cloning and human genome designA conversation for builders, founders, and technologists thinking about biology as the next software layer. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.infinitacitytimes.com

Today, we're joined by Professor Matthew Wood, a leading figure in neuroscience and RNA-based therapeutics. He is Professor of Neuroscience at the University of Oxford, Deputy Head of the Medical Sciences Division, and Director of both the MDUK Oxford Neuromuscular Centre and the Oxford-Harrington Rare Disease Centre, a groundbreaking partnership between the University of Oxford and Harrington Discovery Institute dedicated to accelerating therapies for rare genetic diseases affecting millions worldwide.In today's episode we discuss his vision for making antisense oligonucleotides (or ASOs) and gene editing more modular, more scalable, and faster by collaborating with regulators, scientists, and patient groups to bring hope to those with rare neuromuscular and genetic conditions.With rare disease day coming up just next week, I hope you enjoy the insights that Professor Wood shares on the future of the fight against rare disease.01:23 – Meet Matthew Wood07:26 – The Oxford-Harrington Rare Disease Centre10:33 – Collaborations, philanthropy, and industry partnerships13:55 – Key challenges in rare disease therapy development20:00 – Modular and scalable platforms for ASOs28:08 – Scaling gene editing like CRISPR for rare diseases32:38 – Role of AI and computational tools in acceleration37:28 – Future breakthroughs in rare disease treatments44:07 – Advice for new researchers in the fieldInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Prader Willi syndrome: five much-anticipated therapies poised for approval First-ever approval for Barth Syndrome treatment: what does this mean for ultra-rare disease therapeutics? When rare diseases are not so rare after all: A closer look at where and why this happens

Patrick Bet-David and Rhonda Patrick explore AI's explosive rise, gene therapy, CRISPR, stem cell reprogramming, and longevity breakthroughs. They debate designer genetics, IQ enhancement, organ regeneration, and whether the future belongs to superhumans or authentic human imperfection.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jared Bauer, Cofounder and CEO at Seek Labs, talks about his adventures in company turnarounds, and setting up Seek Labs to improve patient diagnoses and to discover and develop new treatments for infectious diseases. Jared explains the technology convergence that was needed to build Seek Labs' AI diagnostic and CRISPR-based therapeutics platform, an African Swine Fever proof-of-concept study that reduced viremia in pigs, mapping pathogens for rapid target design, and engaging with the FDA and global regulatory agencies.       Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

I'm going to introduce us to a map of North America. It is an old map, but it is contemporary as well. It's the Technate Map of America. Pastor Gene Pensiero Find audio, video, and text of hundreds of other prophecy updates at: https://calvaryhanford.com/prophecy Read along with us at https://calvaryhanford.substack.com Follow us on YouTube at […]

Young people are bio-hacking and gene-hacking in the absence of adult supervision. An emulated personality become an event host. Slice and scan brain digitizers are found. People want to use these to upload to the cloud but there are some grave problems involved. Grace gets a message on her computer from someone or something. Hacking her computer should be impossible. It could be a talented hacker or a super AI left over after the fall of civilization. Lenny is having girl troubles.Mag tech flooring that levitates shoes slightly above the ground to reduce friction and allow controlled sliding movement.  Lifter bots that are headless robotic machines with grippers used for heavy lifting, transport, and forced entry.  Air-gesture control systems that let users operate machines and interfaces through mid-air hand movements.  Gene-hacking technologies that allow people to alter physical traits such as skin reflectivity, hair color, muscle mass, height, and eye color.  Engineered ogra plants that function as a food source, structural material, and biological air filtration system.  Bio-hacked skin modifications that create metallic, glowing, fluorescent, or patterned skin effects.  Printed clothing with animated images that dynamically change visuals on fabric surfaces.  Contraptions for brain slicing and scanning that destroy the biological brain while attempting to digitize its structure.  Brain scanners designed to capture neural structure for attempted uploading into digital systems.  Uploading systems intended to transfer scanned brains into cloud-based environments.  The cloud infrastructure used to host emulated personalities and digital systems after widespread network collapse.  Emulated personalities (EPs) that are AI systems trained on massive recordings of a person to mimic behavior without scanning their brain.  AR glasses that overlay holographic information, interfaces, and visual enhancements onto the real world.  Holographic eye displays embedded in glasses that mirror the wearer's eye expressions.  Encrypted streaming pendants and bracelets used as personal recording and life-capture devices.  Production automation systems that manufacture tools, machines, and devices with minimal human labor.  Advanced fabrication equipment capable of high-end manufacturing but limited by scarcity of raw materials.  Medicine printers that can fabricate biological materials and advanced hardware like protein-based CPUs.  Protein computer CPUs that use biological substrates instead of traditional silicon for computation.  Material simulators that computationally discover novel materials and predict their properties.  Machine Evolver software that simulates machines under real-world physics and evolves designs through virtual iteration.  Knotts math, a radically new mathematical framework that functions as both math and machine language.  Knotts programming language derived from knotts math and used to build operating systems and software.  Custom Linux operating systems rewritten around knotts math principles.  SSH-based remote access systems used to control computers and robots across networks.  Assist, a pervasive AI helper that manages security, media generation, device control, and logistics.  Design expert emulated personalities used to contribute specialist knowledge to engineering projects.  AI systems that convert legacy software into knotts-based programming languages.  Virtual machine crossbreeding networks that allow simulated designs to recombine traits and evolve faster.  E-paper tablets used for low-power note-taking, sketching, and code analysis.  YattaZed remote programming software used to control robots at the administrator level.  YattaSwarm GUIs that manage coordinated groups of robots as a collective system.  Blind-relay networking techniques that disguise communication paths to evade surveillance.  Door operating systems that act as networked nodes capable of running code and relaying messages.  Artificial superintelligence (ASI) that surveils human activity and suppresses certain technologies like knotts.  Digitized hume brains created by scanning and emulating real human brains rather than approximating them with AI.  Neural emulators that provide a computational environment capable of running a full digitized brain.  Virtual reality worlds repurposed as living environments for emulated minds.  Insta-movie generation systems that create personalized films on demand using AI.  Event AI controllers that manage live performances, streaming, lighting, and audience interaction.  Holographic projection systems that display life-sized interactive personalities like Guru Frisky.  Fiber optic hair strands woven into hairstyles to produce glowing light effects.  Exoskeleton suits that augment movement and interface with VR systems.  Mag plate floors used with exoskeletons to allow free-floating VR locomotion.  Advanced VR rigs that replace fixed robotic arms with wearable movement systems.  AI-generated optical illusion art that responds to prolonged visual focus.  3D printing systems capable of producing statues, clothing, tools, and components from various materials.  Mist crystal composite printing materials used as a lightweight alternative to legacy plastics.  Biotic makeup that integrates into the skin rather than sitting on the surface.  CRISPR-based gene editing equipment used by individuals for self-modification.  Viral vector printers that dispense customized gene-editing serums.  Scan-measured clothing printers that adjust garment dimensions as bodies change.  Pain-dampening genetic modifications that reduce or block physical pain responses.  Metabolic enhancement gene edits that increase energy efficiency and muscle performance.  Straw-sized bots woven into hair that act as decorative, animated micro-robots.  Fire axes used as low-tech tools to breach secured doors when automation fails.Many of the characters in this project appear in future episodes.Using storytelling to place you in a time period, this series takes you, year by year, into the future. From 2040 to 2195. If you like emerging tech, eco-tech, futurism, perma-culture, apocalyptic survival scenarios, and disruptive science, sit back and enjoy short stories that showcase my research into how the future may play out. The companion site is https://in20xx.com These are works of fiction. Characters and groups are made-up and influenced by current events but not reporting facts about people or groups in the real world. This project is speculative fiction. These episodes are not about revealing what will be, but they are to excited the listener's wonder about what may come to pass.Copyright © Cy Porter 2026. All rights reserved.

Audra Lynn Fasano joins Tony to share her firsthand experience of being drawn into Jeffrey Epstein's network, beginning with her time at the Playboy Mansion and escalating into blackmail, intelligence ties, and operating as a middleman between elites. She recounts how threats against her family forced her deeper into the web, and why she believes Epstein was only one cog in a much larger machine. The conversation moves beyond trafficking into increasingly dark territory, ritual abuse, bloodline targeting, CRISPR technology, transhumanism, and what Audra sees as a modern Babylonian control system still unfolding today. She connects ancient sites, Nephilim lore, and elite funding networks to current technological initiatives, arguing that the end goal reaches far beyond exploitation. Through it all, Audra emphasizes spiritual warfare, deliverance, and returning to Christ as the only true protection in an escalating battle. This is a sobering discussion about power, deception, and why discernment may be more critical now than ever.Please pray for Tony's wife, Lindsay, as she battles breast cancer. Your prayers make a difference!If you're able, consider helping the Merkel family with medical expenses by donating to Lindsay's GoFundMe: https://gofund.me/b8f76890Become a member for ad-free listening, extra shows, and exclusive access to our social media app: theconfessionalspodcast.com/joinThe Confessionals Social Network App:Apple Store: https://apple.co/3UxhPrhGoogle Play: https://bit.ly/43mk8kZThe Counter Series Available NOW:The Counter (YouTube): WATCH HEREThe Counter (Full Episode): WATCH HEREThe Big Picture Prophecy Conference: prophecyconference26.comTony's Recommended Reads: slingshotlibrary.comIf you want to learn about Jesus and what it means to be saved: Click HereBigfoot: The Journey To Belief: Stream HereThe Meadow Project: Stream HereMerkel Media Apparel: merkmerch.comMy New YouTube ChannelMerkel IRL: @merkelIRLMy First Sermon: Unseen BattlesSPONSORSSIMPLISAFE TODAY: simplisafe.com/confessionalsGHOSTBED: GhostBed.com/tonyCONNECT WITH USWebsite: www.theconfessionalspodcast.comEmail: contact@theconfessionalspodcast.comAudra Lynn FasanoFacebook | Unseen Targets | Unseen Chains | Unseen SpiritsEpstein Justice - Click HereMAILING ADDRESS:Merkel Media257 N. Calderwood St., #301Alcoa, TN 37701SOCIAL MEDIASubscribe to our YouTube: https://bit.ly/2TlREaIReddit: https://www.reddit.com/r/theconfessionals/Discord: https://discord.gg/KDn4D2uw7hShow Instagram: theconfessionalspodcastTony's Instagram: tonymerkelofficialFacebook: www.facebook.com/TheConfessionalsPodcasTwitter: @TConfessionalsTony's Twitter: @tony_merkelProduced by: @jack_theproducerOUTRO MUSICJoel Thomas - "Rose In A Cage"YouTube | Apple Music | Spotify

 Ryan Clarke, Co-Founder, CEO, and CTO of Syntax Bio, is focused on solving manufacturing challenges in producing stem cell-derived therapies, specifically the process of stem cell differentiation. The Cellgorithm platform was designed to make differentiation an engineering problem by using a modified form of CRISPR to turn genes on and off in a specific, controlled sequence, reducing processing time from months to days and resulting in cost savings. One goal is to use AI and machine learning to build models capable of predicting optimal gene regulation sequences accelerating the discovery of new differentiation protocols and treatments for degenerative diseases. Ryan explains, "The key problem that we are focused on applies to stem cell-derived cell therapies. And so, just for a little bit of context setting, we use induced pluripotent stem cells or IPS cells. And about 20 years ago, when these were first derived, everybody was very excited because this is the platform where you could then have an infinite supply of stem cells to then make any tissue-specific cell type at will, theoretically. Fast forward 20 years, and there are finally some cell therapies in phase three clinical trials, but none are approved yet. And that just tells you that the development cycle for this modality is actually slower than the other modalities, like biologics or small molecules. And the problem is manufacturing in particular, or how do you convert the stem cell into the target tissue cell type for the process of stem cell differentiation? And so we are solely focused on making stem cell differentiation an engineering problem rather than a kind of dark art."   "We have a program for type one diabetes that is making pancreatic beta cells from IPS cells. And we have also done some work in the musculoskeletal system. So these other cell types we focus on are more demonstrations of the platform technology, but we are interested in possibly co-developing those with other pharmaceutical partners, and that's the musculoskeletal cells of the hematopoietic system. And we've done some work on retinal cells as well, but we endeavor to make many other cell types. And our goal is to partner with the therapeutic experts in the area to develop these." #SyntaxBio #CellTherapy #CRISPR #StemCells #Biotech #RegenerativeMedicine #Diabetes #Manufacturing #Innovation #GeneTherapy #LifeSciences #Bioengineering #SyntheticBiology #CellProgramming syntax-bio.com Listen to the podcast here

 Ryan Clarke, Co-Founder, CEO, and CTO of Syntax Bio, is focused on solving manufacturing challenges in producing stem cell-derived therapies, specifically the process of stem cell differentiation. The Cellgorithm platform was designed to make differentiation an engineering problem by using a modified form of CRISPR to turn genes on and off in a specific, controlled sequence, reducing processing time from months to days and resulting in cost savings. One goal is to use AI and machine learning to build models capable of predicting optimal gene regulation sequences accelerating the discovery of new differentiation protocols and treatments for degenerative diseases. Ryan explains, "The key problem that we are focused on applies to stem cell-derived cell therapies. And so, just for a little bit of context setting, we use induced pluripotent stem cells or IPS cells. And about 20 years ago, when these were first derived, everybody was very excited because this is the platform where you could then have an infinite supply of stem cells to then make any tissue-specific cell type at will, theoretically. Fast forward 20 years, and there are finally some cell therapies in phase three clinical trials, but none are approved yet. And that just tells you that the development cycle for this modality is actually slower than the other modalities, like biologics or small molecules. And the problem is manufacturing in particular, or how do you convert the stem cell into the target tissue cell type for the process of stem cell differentiation? And so we are solely focused on making stem cell differentiation an engineering problem rather than a kind of dark art."   "We have a program for type one diabetes that is making pancreatic beta cells from IPS cells. And we have also done some work in the musculoskeletal system. So these other cell types we focus on are more demonstrations of the platform technology, but we are interested in possibly co-developing those with other pharmaceutical partners, and that's the musculoskeletal cells of the hematopoietic system. And we've done some work on retinal cells as well, but we endeavor to make many other cell types. And our goal is to partner with the therapeutic experts in the area to develop these." #SyntaxBio #CellTherapy #CRISPR #StemCells #Biotech #RegenerativeMedicine #Diabetes #Manufacturing #Innovation #GeneTherapy #LifeSciences #Bioengineering #SyntheticBiology #CellProgramming syntax-bio.com Download the transcript here

Meet Billy Carson in Atlanta Mar 1st https://www.unlockdivinitycodes.com/Billy Carson will mentor you free for days. https://4bkacademy.com30 Day Free Trial Of 4biddenknowledge.TV 30 Day Free Trial On 4biddenknowledge.TVSupport the show

Meet Billy Carson in Atlanta Mar 1st https://www.unlockdivinitycodes.com/Billy Carson will mentor you free for days. https://4bkacademy.com

CEREMONIAL SCI OP - 02.09.2026 - #914 BestPodcastintheMetaverse.com Canary Cry News Talk #914 - 02.09.2026 - Recorded Live to 1s and 0s Deconstructing World Events from a Biblical Worldview Declaring Jesus as Lord amidst the Fifth Generation War! CageRattlerCoffee.com SD/TC email Ike for a discount https://CanaryCry.Support   Send address and shirt size updates to canarycrysupplydrop@gmail.com Join the Canary Cry Roundtable This Episode was Produced By:   Executive Producers Michael B*** Sir LX Protocol Baron of the Berrean Protocol***   Producers of TREASURE (CanaryCry.Support) Cage Rattler Coffee   Producers of TIME Timestampers: Jade Bouncerson, Morgan E Clankoniphius Links: JAM   SUPPLY DROP Calendar and Goldback bonus to new sign ups   OLYMPICS DEVIL 2:48 Ring "Search party"  Clip: Olympics Pentagram Clip: Spiral imagery at opening ceremony (X) Clip: Israeli's boo'd at opening ceremony, walking through Stargate (X) Clip: Israel boo'd? (X)  Israeli Bobsled team Robbed (Fox) → Clip: Milan protests are intense → Clip: more protest footage AP gives no reason for riots at Olympics (AP) → DHS post, sent ICE agents to Italy for Olympics, quotes Variety (X)  Suspected saboteurs hit Italian rail network near Bologna, police say (CBC)   EPSTEIN 1:33:28 Note: France former culture minister resigns over Epstein (AP) Cclip: Ro Khana on the destruction of the royal family (cnn)  'Evil': Conservatives ERUPT on Steve Bannon Over Epstein Revelations (MediaIte) Epic Games denies rumors about presence of Jeffrey Epstein alive and playing Fortnite (MSN) Epstein heavily involved in "Micro-transactions" in video games Epstein WoW account and money laundering (IBT)   -Epstein Reportedly Ordered Multiple 55-Gallon Sulfuric Acid in 2018: 'Likely Used to Dissolve Bodies of Children' (IBT) → 330-Gallon Sulfuric Acid Purchase in 2018 Sparks Speculation (Criminal Watch) → He ordered 6x55 gallons which = 330 (X)   SCIENCE IS TRUTH 2:26:33 1-CRISPR removes chromosome to cure Down syndrome (Time of India) → Innovative Approach Developed for Removing Extra Chromosome 21 in Cells from Individuals with Down Syndrome Using CRISPR-Cas9 Genome Editing Technology (MIE) 2-First human trials of locally-developed HIV jab begin in South Africa (Yahoo/Telegraph) 3-Mexican Researchers Breakthrough That Could Lead to Complete Elimination of HPV (I24)   CANCER 2:30:55 4-Spanish scientists cure pancreatic cancer in mice in medical breakthrough (Fox) 5-Korean Scientists Reversed Colon Cancer Cells to Normal State (Open Gate Media) 6-Precision conversion of colorectal cancer lung metastases (NIH) 7-Russia unveils first test batches of cancer vaccine (RT) 8-Scientists discover 'levitating' time crystals that you can hold in your hand (Phys.org) 9-New type of magnetism discovered in 2D materials (Phys.org) Clip: Uncles Tremble as Man Invents Vaccine Delivered by Beer (Futurism)   GATES OF THE GODS/SPACE 2:39:29 *Scientists Say Heck, Just Nuke a Killer Asteroid Heading for Earth (Futurism)   EXECUTIVE PRODUCERS 2:47:57 TALENT/TIME 3:00:25 END 3:12:08

Biotechnology is advancing faster than ever before, and the stakes have never been higher. In this episode, Dr. Christopher Cummings, lead for the Center for Health Engineering with the U.S. Army Corps of Engineers, breaks down why the convergence of biotech and artificial intelligence is creating both unprecedented opportunities and existential risks. From gene-edited foods that could revolutionize agriculture to AI-designed viruses that could destabilize nations, Dr. Cummings explores the delicate balance between innovation and oversight. He reveals why traditional regulatory frameworks are struggling to keep pace and how "information hazards" are forcing scientists to rethink transparency itself. We dive into the ethical minefield of black-boxed AI systems, designing biological solutions, the growing trust gap between lab and consumer, and what it means when AI can "de-skill" biotechnology to the point where expertise is no longer required to create dangerous organisms.  Topics covered: CRISPR and gene editing, AI convergence, biosafety and bioweapons, public trust in GMOs, generational attitudes toward biotech, risk communication, international cooperation, and the future of governance in an accelerating technological landscape.

HEADLINE: Charles Lieber and the CRISPR Threat. GUEST: Brandon Weichert. SUMMARY: Weichert highlights Charles Lieber's conviction and He Jiankui's unethical gene experiments, illustrating how China exploits dual-use biotechnology to advance military goals and defeat Western rivals.PEKING 1904

Contributor: Alec Coston, MD Educational Pearls: Disclaimer: this has nothing to do with the ER but is too cool to not talk about. Condition: Carbamoyl phosphate synthetase 1 (CPS1) deficiency Rare inborn error of metabolism Inability to properly break down ammonia Leads to severe hyperammonemia and hepatic encephalopathy Natural history: Without treatment, typically fatal within the first few weeks of life Even with current standard treatments, life expectancy is often limited to ~5–6 years Breakthrough treatment: A team of researchers at the Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania developed the CRISPR-based targeted gene therapy for this patient. First-of-its-kind precision approach tailored to the patient's specific mutation Key components of the therapy: Whole-genome sequencing to identify the exact CPS1 mutation Creation of a custom base-editing enzyme designed to correct that specific mutation Design of a guide RNA to direct the base editor to the precise genomic location Delivery method: Lipid nanoparticles used to deliver the gene-editing machinery Nanoparticles can be targeted to specific tissues Why the liver works well: CPS1 is primarily expressed in hepatocytes The liver is relatively easy to target with lipid nanoparticles Hepatocytes divide frequently, allowing edited genes to be passed on as cells replicate Long-term impact: Once edited, cells continue producing functional CPS1 enzyme Potential for durable, possibly lifelong correction from a single treatment References https://www.nih.gov/news-events/news-releases/infant-rare-incurable-disease-first-successfully-receive-personalized-gene-therapy-treatment Choi Y, Oh A, Lee Y, Kim GH, Choi JH, Yoo HW, Lee BH. Unfavorable clinical outcomes in patients with carbamoyl phosphate synthetase 1 deficiency. Clin Chim Acta. 2022 Feb 1;526:55-61. doi: 10.1016/j.cca.2021.11.029. Epub 2021 Dec 29. PMID: 34973183. Bharti N, Modi U, Bhatia D, Solanki R. Engineering delivery platforms for CRISPR-Cas and their applications in healthcare, agriculture and beyond. Nanoscale Adv. 2026 Jan 5. doi: 10.1039/d5na00535c. Epub ahead of print. PMID: 41640466; PMCID: PMC12865601. Summarized and edited by Jeffrey Olson MS4 Donate: https://emergencymedicalminute.org/donate/ Join our mailing list: http://eepurl.com/c9ouHf

Welcome back for some Unfiltered Conspiracy! Mormons always show up this is true… however this one was surprising even to me! The occult, while meaning hidden also has a dark definition as well.What goes on behind the lives of the top elites? What happened at the ranch owned by Epstein?DNA manipulation, CRISPR and Howard Hughes all make an appearance. All of this is confusing and maybe it's meant to be..However remember there is always two truths and a lie! Let's dive in and see what we flush out with Ben from Tree of Liberty Podcast.Give him a follow at his link belowGuest Links: https://treeoflibertysociety.com/X: https://x.com/treeoflibertys/status/1999181800716001608?s=46Unfiltered Rise Podcast Links Website: https://unfilteredrisepodcast.com/Patreon: https://patreon.com/UnfilteredRise?IG: https://www.instagram.com/unfilteredrise_podcast?igsh=MWE4NnQ2Y2Zxa3pnNw%3D%3D&utm_source=qrYouTube: https://youtube.com/@unfilteredrisepodcast?si=GP1pu_CC8kkvNlFyX: https://x.com/unfilteredrise/status/1772012349551153303?s=46TikTok: https://www.tiktok.com/Merch: https://heidi-luv-shop.fourthwall.com/Donations: https://www.buymeacoffee.com/unfilteredEPlease subscribe if you haven't all ready and consider supporting my work! There are several books I need and am working towards.A review and subscribing is just as precious if you cannot! Ty to you all! God Bless and all glory to him each and every day! Please know my podcast and its information presented are for entertainment or informational purposes. I do not threaten or wish any harm to any nation,creed, color, religion etc …. #Utah #Mormonism #Epstein #Mormon #LDS #history #occultmormonism #Epsteinfiles #Mormonblood #Unfilteredconspiracy

On this episode of Purple Political Breakdown, host Radell Lewis dives deep into the newly released Epstein files, breaking down the 3.5 million pages of DOJ documents and what they reveal about Donald Trump, Bill Clinton, Elon Musk, Bill Gates, Prince Andrew, and other high-profile names. Who's being protected by the redactions, and why are victims being exposed while powerful men stay hidden? Then Radell tackles the gas prices myth head-on with a full research segment on how gas prices actually work from crude oil and OPEC production decisions to refinery closures and global supply and demand and why no U.S. president, Republican or Democrat, controls what you pay at the pump. Plus: Operation Metro Surge and the ICE crackdown in Minnesota, the FBI's raid on Fulton County's election office with Tulsi Gabbard on speakerphone with Trump, the massive Democratic special election upset in Texas, Trump's cratering approval ratings, how Twitter's algorithm is skewing political reality, the measles outbreak under RFK, and the 2026 midterms outlook. The show wraps with ten good news stories the media won't tell you about, from CRISPR gene therapy breakthroughs to malaria vaccine success in Ghana. Political solutions without political bias. New episodes every Sunday at 8 AM EST. Keywords: Epstein files, Epstein documents release, Trump Epstein, Clinton Epstein, Elon Musk Epstein, gas prices explained, who controls gas prices, OPEC, crude oil prices, ICE Minnesota, Operation Metro Surge, Fulton County FBI raid, 2026 midterms, Trump approval rating, Twitter algorithm bias, election integrity, tariffs, political podcast, nonpartisan politics, Purple Political Breakdown, Radell Lewis, Alive Podcast NetworkStandard Resource Links & RecommendationsThe following organizations and platforms represent valuable resources for balanced political discourse and democratic participation: PODCAST NETWORKALIVE Podcast Network - Check out the ALIVE Network where you can catch a lot of great podcasts like my own, led by amazing Black voices. Link: https://alivepodcastnetwork.com/ CONVERSATION PLATFORMSHeadOn - A platform for contentious yet productive conversations. It's a place for hosted and unguided conversations where you can grow a following and enhance your conversations with AI features. Link: https://app.headon.ai/Living Room Conversations - Building bridges through meaningful dialogue across political divides. Link: https://livingroomconversations.org/ UNITY MOVEMENTSUs United - A movement for unity that challenges Americans to step out of their bubbles and connect across differences. Take the Unity Pledge, join monthly "30 For US" conversation calls, wear purple (the color of unity), and participate in National Unity Day every second Saturday in December. Their programs include the Sheriff Unity Network and Unity Seats at sports events, proving that shared values are stronger than our differences. Link: https://www.us-united.org/ BALANCED NEWS & INFORMATIONOtherWeb - An AI-based platform that filters news without paywalls, clickbait, or junk, helping you access diverse, unbiased content. Link: https://otherweb.com/ VOTING REFORM & DEMOCRACYEqual Vote Coalition & STAR Voting - Advocating for voting methods that ensure every vote counts equally, eliminating wasted votes and strategic voting. Link: https://www.equal.vote/starFuture is Now Coalition (FiNC) - A grassroots movement working to restore democracy through transparency, accountability, and innovative technology while empowering citizens and transforming American political discourse. Link: https://futureis.org/ POLITICAL ENGAGEMENTIndependent Center - Resources for independent political thinking and civic engagement. Link: https://www.independentcenter.org/ GET DAILY NEWSText 844-406-INFO (844-406-4636) with code "purple" to receive quick, unbiased, factual news delivered to your phone every morning via Informed (https://informed.now) ALL LINKShttps://linktr.ee/purplepoliticalbreakdownThe Purple Political Breakdown is committed to fostering productive political dialogue that transcends partisan divides. We believe in the power of conversation, balanced information, and democratic participation to build a stronger society. Our mission: "Political solutions without political bias."Subscribe, rate, and share if you believe in purple politics - where we find common ground in the middle! Also if you want to be apart of the community and the conversation make sure to Join the Discord: https://discord.gg/ptPAsZtHC9

Episode 344 Elon Musk has announced he wants to merge SpaceX with another of his companies, xAI, and launch one million satellites into space. One reason - according to Musk - is to eventually harness the entire power of the sun, a sci-fi sounding idea that would make us a Kardashev Type II civilisation. But he also wants the satellites to help power AI and move data centres off Earth. Is his goal realistic… and what would be the consequences? Parents desperate to get their children to sleep are resorting to melatonin gummies - and it's proving very effective. Melatonin is a sleep hormone which is only available on prescription in many countries. So some parents are importing them from America - where they can be bought over-the-counter. The trouble is the long-term side effects are not really known - and cases of melatonin overdose in children are on the rise. Despite global agreement to cut the "overall risk" from pesticides by at least half by 2030 - new data shows we're not even close. Countries made this commitment at a UN biodiversity meeting in 2022, but so far it's been almost impossible to measure success. Thanks to a researcher in Germany, we now have a way to track our progress - and it's not looking good. Could an increase in organic farming be the solution, or CRISPR gene editing? Hosted by Rowan Hooper and Penny Sarchet, with guests Jonathan O'Callaghan, Alice Klein and Michael Le Page. To read more about these stories, visit https://www.newscientist.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Wow what do cabbage babies, bloodlines, Crispr, and History especially of the orphan trains have in common?It may be more that you think! This wild research of mine is not new... this has been a question for me since I started my podcast almost 4 years ago.Knowing about Mormons, Utah and Genetics I went down the research road trying to find some answers.Especially now I am even more interested seeing the many strange pieces of the Epstein files, and of course as I always say some Mormons were there!I can't make it up thats for sure... So buckle up for a wild ride on this one and trigger warning for some sensitive photos. A big Thank You to Greyhorn Pagans for sharing the show and Please follow all of his work at the links below! Greyhorn Pagans https://www.greyhornpagans.com/https://open.spotify.com/show/03NlRDGZgczxwPaLh3ZX4j?si=iDt7X83ZRNWMlvk2328vhgUnfiltered RIse Podcast LinksWebsite: https://unfilteredrisepodcast.com/Patreon: https://patreon.com/UnfilteredRise?X: https://x.com/unfilteredrise/status/1772012349551153303?s=46IG: https://www.instagram.com/unfilteredrise_podcast?igsh=MWE4NnQ2Y2Zxa3pnNw%3D%3D&utm_source=qrYouTube: https://youtube.com/@unfilteredrisepodcast?si=IMlOVdcKU6oj4N8sTikTok: https://www.tiktok.com/@unfilteredrisepodcast?_t=8rjVXGsH2AY&_r=1Merch: https://heidi-luv-shop.fourthwall.com/Donations: buymeacoffee.com/unfilteredEPlease know my podcast and its information presented are for entertainment or informational purposes. I do not threaten or wish any harm to any nation,creed, color, religion etc …. God Bless

Juanjo de la Iglesia nos habla en 'Las Claves de La Brújula' sobre esta revolucionaria herramienta de modificación genética y sus implicaciones para la humanidad.

OPERATION NEPHILIM BUZZ - 02.04.2026 - #913 BestPodcastintheMetaverse.com Canary Cry News Talk #913 - 02.04.2026 - Recorded Live to 1s and 0s Deconstructing World Events from a Biblical Worldview Declaring Jesus as Lord amidst the Fifth Generation War! CageRattlerCoffee.com SD/TC email Ike for discount https://CanaryCry.Support   Send address and shirt size updates to canarycrysupplydrop@gmail.com Join the Canary Cry Roundtable This Episode was Produced By:   Executive Producers Sir Jamey Not the Lanister*** Sir LX Protocol Baron of the Berrean Protocol***   Producers of TREASURE (CanaryCry.Support) Cage Rattler Coffee, Alex W, Mrs TinfoilHatMan, Veronica D, Sir Scott Knight of Truth, Sir Casey    Producers of TIME Timestampers: Jade Bouncerson, Morgan E Clankoniphius Links: JAM   5GW 9:46 V CIA is recruiting Data Lifecycle analysts (X)   NEPHILIM UPDATE 27:01 V Viking-era burial pit filled with decapitated and mutilated bodies including 'giant' with 'hole in his skull' is found on outskirts of British city (DailyMail) Candace Nephilim Episode   BIBLICAL 48:38 V Polymarket: Jesus will return in 2027, doubles (X)   PANDEMIC SPECIAL 53:11 V CLIP: More info on the labs B1 person is arrested after a suspected biolab is found at Las Vegas home (AP) CRISPR: Senate Republican on suspected biolab found in LV: 'Enormous problem' (The Hill)   SEWER SURVEILLANCE 1:10:51 V -The Secret Weapon in Canada's Sewers (Maclean's CA) → Smart sanitary hardware for health monitoring (Nature)   EPSTEIN 1:24:55 V Zohran MamDanis mother appears in the epstien docs (SNOPES) Mira Nair was Married to Mitch Epstien (wiki) Zohran Epstein side by side 1 Zohran Epstein Side by side 2 → Was Epstein Andrew Jackson?   EXECUTIVE PRODUCERS TALENT/TIME END

Alberto Ciccia, Professor of Genetics and Development at Columbia University, joins us to discuss how cells protect their genomes and how these pathways intersect with cancer and immunity. He explains how his lab uses CRISPR-based genome-editing tools to map the DNA damage response and uncover new therapeutic targets. We also talk about his recent Cell study showing how the DNA damage response factor SMARCAL1 shapes immune signaling and tumor immune evasion. Throughout the conversation, Professor Ciccia reflects on mentorship, scientific creativity, and how advances in DNA repair research could translate into better diagnostics and treatments for patients.Hosted by Sophia Deng.

We love to hear from our listeners. Send us a message.In episode 121 of Cell & Gene: The Podcast, Host Erin Harris talks to Scribe Therapeutics' CEO and Co-Founder Benjamin Oakes about building next‑generation CRISPR and epigenetic editing tools to move genetic medicine beyond rare disease into common cardiometabolic indications. Oakes shares Scribe's engineered CasX platform and epigenetic silencers, preclinical data from its various programs, and why exquisite specificity and low-dose LNP delivery are essential to treating patients safely. They also explore Scribe's partnerships with Sanofi and Lilly, the company's cardiometabolic-first strategy co-developed with Dr. Jennifer Doudna, and Oakes' conviction that genetic medicines can fundamentally reshape healthspan and the future of preventive cardiovascular care.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

When it comes to “bad” cholesterol, most cardiologists say lower is better. But what's the best way to get that number down? Can diet and exercise alone do the job?Cardiologists Kiran Musunuru and Neha Pagidipati join Host Ira Flatow for a look at the latest in cholesterol-lowering treatments, including CRISPR technology that could turn off cholesterol-making genes for life. How does it work, and is it safe?Guests:Dr. Kiran Musunuru is the scientific director of the Center for Inherited Cardiovascular Disease at the Perelman School of Medicine at the University of Pennsylvania.Dr. Neha Pagidipati is the director of the Cardiometabolic Prevention Clinic at the Duke University School of Medicine in Durham, NC.Transcripts for each episode are available within 1-3 days at sciencefriday.com.  Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Mary Shelley's Frankenstein continues to captivate audiences centuries after its publication, but not all adaptations emphasize the same ethical questions. Matthew and returning guest AK dive into both the original novel and Guillermo del Toro's recent film adaptation—not to catalog their differences, but to explore how each medium handles the story's core moral dilemmas and which approach proves more compelling.How Does the Film Emphasize “The Other” Differently?While both the book and film explore themes of parentage, responsibility, and scientific hubris, they emphasize different ethical questions. AK notes that the novel places stronger emphasis on the responsibilities of individuals in medicine and parenting, particularly through the lens of abandonment. The film, however, foregrounds questions about the grotesque other, the monstrous other, and how appearance shapes moral judgment. The visual decisions in del Toro's adaptation—juxtaposing the creature against beautiful backdrops that shift with emotional moments—underscore this emphasis.How Does the Shift from Abandonment to Abuse Change Victor's Responsibility?One of the most striking differences between the book and film lies in Victor Frankenstein's initial interaction with his creation. In Shelley's novel, Victor creates the monster, goes to bed, wakes up, and immediately flees—abandoning the creature with almost no interaction. Del Toro's film takes a dramatically different approach: Victor spends considerable time with the creature, engaging with it in ways impossible in the book. This changes the fundamental ethical question. Does Victor bear responsibility for abandonment and neglect, or for intentional, directed abuse? The film's choice to show an extended period of interaction—where Victor treats the creature as an object rather than a being—shifts the moral weight of his culpability.Why Does the Composite Body Matter More Now Than Ever?Victor's method of selecting “optimal” body parts from different corpses to create his creature resonates uncomfortably with contemporary debates about human enhancement and biotechnology. The discussion explores how Victor's approach—viewing the creature as an optimization project rather than a living being—connects to modern questions about CRISPR, genetic modification, and who decides what constitutes an “optimal” human body. These questions inevitably involve ableism and the commodification of bodies. The film's emphasis on Victor literally selecting bodies at prisons raises urgent parallels to current concerns: Who becomes test subjects for experimental procedures like Neuralink? Are they being viewed as humans or as subjects for experimentation?Other Topics Covered:Why the novel's nested narrative structure (stories within stories) creates a unique moral complexityHow both works explore humanity's relationship to nature, science, and the line between achievement and hubrisThe challenge of adapting works from different historical contexts when what counted as scientific hubris has radically changedThe concept of viewing people as player characters (with their own interiority) versus non-player characters (existing only to advance your plot)Why Frankenstein's relevance grows as biotechnology makes questions of life preservation more immediateThe conversation reveals how both Shelley's novel and del Toro's film use the Frankenstein story to explore timeless questions through different emphases—one focusing on neglect and parental failure, the other on abuse and the othering of those who don't meet conventional standards of beauty or normalcy. **************************************************************************This episode is a production of Superhero Ethics, a The Ethical Panda Podcast and part of the TruStory FM Entertainment Podcast Network. Check our our website to find out more about this and our sister podcast Star Wars Generations.We want to hear from you! You can keep up with our latest news, and send us feedback, questions, or comments via social media or email.Email: Matthew@TheEthicalPanda.comFacebook: TheEthicalPandaInstagram: TheEthicalPandaPodcastsTwitter: EthicalPanda77Or you can join jump into the Star Wars Generations and Superhero Ethics channels on the TruStory FM Discord.Want to get access to even more content while supporting the podcast? Become a member! For $5 a month, or $55 a year you get access to bonus episodes and bonus content at the end of most episodes. Sign up on the podcast's main page. You can even give membership as a gift!You can also support our podcasts through our sponsors:Purchase a lightsaber from Level Up Sabers run by friend of the podcast Neighborhood Master AlanUse Audible for audiobooks. Sign up for a one year membership or gift one through this link.Purchase any media discussed this week through our sponsored links.

Avancerad genteknik används för att ta fram grisar som står emot klassisk svinpest genom att slå ut proteiner som viruset är beroende av. Lyssna på alla avsnitt i Sveriges Radios app. Klassisk svinpest är en virussjukdom som historiskt lett till masslakt, hårda avspärrningar och stora ekonomiska förluster. Med avancerad genteknik tas nu steg mot djur som inte längre kan infekteras av viruset. Arbetet bygger på att slå ut ett protein som viruset är beroende av för att föröka sig i grisens celler. När proteinet inte längre bildas stoppas smittan innan sjukdomen bryter ut.Forskare i Storbritannien och Kina har oberoende av varandra tagit fram grisar som visat tydlig motståndskraft mot klassisk svinpest, och resultaten imponerar erfarna veterinärmedicinare. Tekniken bygger på gensaxen CRISPR, där en exakt genförändring görs utan att påverka djurens tillväxt, reproduktion eller köttkvalitet enligt de uppföljningar som hittills gjorts.Samtidigt är hotet från svinpest större än på länge. Den afrikanska varianten, svårare och mer komplex, har nått både svenska vildsvin och flera europeiska länder. Forskare bedömer att den också är svårare att komma åt med genredigering och kräver flera genförändringar innan resistenta djur är möjliga.Genredigeringens framsteg öppnar ändå för ett framtida jordbruk där sjukdomar som idag orsakar enorma kostnader kan begränsas direkt i djurens arvsmassa. Frågan är hur snabbt tekniken kan nå marknaden – och om den kan förändra hur avel, smittskydd och livsmedelsproduktion ser ut i grunden.Reporter: Gustaf Klaringustaf.klarin@sr.seProducent: Lars Broströmlars.brostrom@sr.se

Send us comments, suggestions and ideas here! In this week's episode we explore two very real technologies which are just now getting off the ground and promise to completely change not just how we think about life and death itself, but what it means to be human. In the free side of the show we discuss what happens when we turn our dead grandma into a digital avatar we can keep on our phone forever and how this technology will be used to sabotage phone scammers. In the second half of the show we discuss the reality of night-vision eyes, breathing under water, re-growing limbs and Neurolink implants. We really enjoyed working on this one, thank you and enjoy the show!Visit www.patreon.com/TheWholeRabbit to hear the extended show! In this week's episode we discuss:Necro Grandma Babysitter?!AI TwinThe Tibetan Book of the DeadBlack Mirror: “Be Right Back”EcclesiastesRidden By the LoaIn the extended show available at www.patreon.com/TheWholeRabbit we discuss:Night Vision EyesUnderwater Breathing InjectionsLimb Regrowth Customizable EmbroyosNeurolink This episode was written by Heka and Luke with his parts in Red, hers in Purple, Mari in Blue, Chillz in light blue and Tim in black with moral support. Where to find The Whole Rabbit:Spotify: https://open.spotify.com/show/0AnJZhmPzaby04afmEWOAVInstagram: https://www.instagram.com/the_whole_rabbitTwitter: https://twitter.com/1WholeRabbitOrder Stickers: https://www.stickermule.com/thewholerabbitOther Merchandise: https://thewholerabbit.myspreadshop.com/Music By Spirit Travel Plaza:https://open.spotify.com/artist/30dW3WB1sYofnow7y3V0YoSources:2wai - Talking to your dead grandma:https://www.2wai.ai/2wai | Preserve Your LegacyOther Necromancy Apps:HereAfter AI: Where Memories Live ForeverThe Gift of a Lifetime: StoryFile LifeProfluent:https://www.profluent.bio/modality/opencrisprEditing human genome?https://en.wikipedia.org/wiki/He_Jiankui_affairSupport the show

We love to hear from our listeners. Send us a message.Welcome to episode 120 of Cell & Gene: The Podcast. Host Erin Harris is joined by Rachel Haurwitz, CEO of Caribou Biosciences, to discuss the company's progress in developing CRISPR-edited, off-the-shelf CAR-T therapies for hematologic malignancies. Their conversation centers on Vispacell, Caribou's allogeneic CD19 CAR-T for second-line large B-cell lymphoma. Haurwitz explains how Caribou has systematically optimized its allogeneic platform using clinical and translational data. They also cover pivotal Phase 3 trial planning, regulatory considerations, and what to expect next from Caribou's broader pipeline, including its BCMA-targeted program in multiple myeloma.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

Thanks for spending some time with us. We really appreciate all our listeners and hope that these studies through God’s Word have encouraged and inspired you to walk with Him more than ever before. If you’re looking for another study – check out one of our other podcasts. We’ve got dozens going through a variety […]

Investigative researcher Chris Crutchfield joins Faust in-studio to probe the Charlie Kirk investigation narrative: Candace Owens vs. Erica Kirk, ties to the military-industrial complex, and how everything connects to mass mind control in episode 233 of the Far Out with Faust podcast.In this conversation, Faust and Chris examine the Charlie Kirk investigation and the competing narratives that formed around it, including Candace Owens' scrutiny and Erica Kirk's public role. From there, the discussion widens into a deeper examination of psychological warfare, biological and nervous-system–level control, and narrative management, using the Kirk case as one example of how power, perception, and compliance are shaped in real time through both media and physical influence.In this episode:

Broadcast from KSQD, Santa Cruz on 1-01-2025: An emailer asks about omega-3 supplementation for memory at age 72. Dr. Dawn advises checking that fish oil capsules contain adequate DHA—at least 1,000 mg—since many omega-3 products have low DHA levels. She notes Medicare covers the same testing at standard labs as proprietary labs like OmegaQuant that charge patients directly. Beyond omega-3s, she emphasizes glucose control (hemoglobin A1c below 5.6) since the enzyme that breaks down insulin also clears beta-amyloid, and weight training to raise brain-derived neurotrophic factor (BDNF), which promotes new synapse formation essential for memory. Dr. Dawn reviews Popular Science's top 2025 health innovation: eye drops from Lens Therapeutics containing aceclidine that correct age-related farsightedness for 10 hours. The drops shrink the pupil to increase depth of field, improving near vision by three or more lines on eye charts within 30 minutes without affecting distance vision. Side effects include eye irritation, dimmed night vision, and headache. She describes Duke University's breakthrough allowing heart transplants from circulatory death donors using an on-table reanimation technique. This could expand the pediatric donor pool by 20%—critical since up to 20% of children die waiting for transplants. Dr. Dawn celebrates CAR-T immunotherapy for multiple myeloma, which saved her husband's life. Of 97 heavily pretreated patients, 38% achieved complete remission still present at five years, with over 50% total survival. The therapy removes T-cells, uses CRISPR to add receptors targeting cancer cell antigens, then reinfuses the modified cells. She highlights a UC Davis study showing remote blood pressure monitoring with home technology, education, and coaching dropped patients' average blood pressure from 150/80 to 125/74 in months—low-tech with high impact. Dr. Dawn explains the Nano Knife for prostate cancer, which uses localized electrical pulses delivered through thin wires to destroy tumors while sparing surrounding nerves. This minimally invasive approach could reduce erectile dysfunction and incontinence common with traditional surgery. She describes Gilead's Sunlenca, a twice-yearly injection for HIV prevention that's 99% effective. At $14,000 per injection in the US, proceeds help fund access in resource-limited countries where it can be distributed like a vaccination. Dr. Dawn discusses Journavx (suzetrigine), a new non-opioid pain medication working on sodium channels to block pain signals before reaching the brain. At $30 for 50 pills on GoodRx, it offers an alternative for surgical pain in patients with addiction history or genetic vulnerability to opioid dependence. She details the landmark case of Baby KJ, the first person to receive personalized CRISPR gene therapy. Born with a CPS1 enzyme deficiency causing toxic ammonia buildup, KJ was too small for liver transplant. Scientists identified his specific mutation and used CRISPR base editing delivered via lipid nanoparticles to correct a single DNA letter—changing an A to G—in his liver cells which restored enough function to be discharged home. Dr. Dawn reports surprising findings that COVID mRNA vaccines amplify cancer immunotherapy. Lung cancer patients who received COVID vaccination within 100 days of checkpoint inhibitor treatment had 56% three-year survival versus 31% for unvaccinated patients. The mechanism is unknown but may involve mRNA generally alerting the immune system. She revisits research showing Zostavax shingles vaccination reduced dementia risk by 20% over seven years. A natural experiment in Wales—where an age cutoff created comparable vaccinated and unvaccinated groups—provided strong evidence that preventing herpes zoster inflammation protects brain health. Dr. Dawn concludes with Huntington's disease breakthrough: microRNA therapy delivered by virus directly into the brain slowed disease progression by 75% over three years. The microRNA binds to Huntington protein mRNA, preventing ribosome translation and toxic protein production. Some patients returned to work; others expected to need wheelchairs are still walking.

At 3 months old, Victoria Gray wouldn't stop crying. Blood tests brought devastating news: she had sickle cell disease, a genetic blood disorder that blocks blood flow and oxygen delivery to the body. It causes unbearable pain that Victoria describes as “getting struck by lightning and hit by a truck.”As she got older, Victoria felt increasingly isolated and hopeless. She often spent her kids' birthdays at the hospital, where she received regular blood transfusions. “I felt like I was cheating my children out of their childhood,” she says. “I didn't look forward to a long life. I stopped dreaming. I gave up on school or doing anything … I thought that I was close to dying.”But at age 34, Victoria got a new chance at life. In 2019, she became the first person in the world to receive a revolutionary new treatment for the disease — a gene-editing tool called CRISPR discovered in a UC Berkeley lab, which would go on to win a Nobel Prize just one year later. “It felt like an answered prayer for me,” says Victoria. “CRISPR not only freed me, it freed my children.” This is the third episode of our latest Berkeley Voices season, featuring UC Berkeley scholars working on life-changing research — and the people whose lives are changed by it.Listen to the episode and read the transcript on UC Berkeley News (news.berkeley.edu/podcasts/berkeley-voices).Music by Blue Dot Sessions.Photo courtesy of Victoria Gray; illustration by Neil Freese/UC Berkeley. Hosted on Acast. See acast.com/privacy for more information.

Matters Microbial #121: Phollowing Phage in the Gut Microbiome January 7, 2026 Today Dr. Liz de Ora Ortiz, postdoctoral scholar in the Secor Laboratory at Montana State University, joins the #QualityQuorum to discuss a fascinating new technology that allows investigators to follow bacteriophage infections in live animals.   Host: Mark O. Martin Guest: Liz de Ora Ortiz Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode The fascinating and frustrating (for researchers like me) story of Vampirococcus. A Vampirococcus summary for new #Micronauts. An overview of Agrobacterium, a bacterium about which all micronauts should know (think about genetic engineering in agriculture!). The story of Pelagibacter, very probably the most abundant organism on Earth.    The story of Akkermansia, and its impact on metabolic health and the gut microbiome. An important essay by the late Dr. Elio Schaechter regarding paradigm shifts in microbiology.  Much recommended! A truly wonderful video about bacteriophages and their importance. A simple video explaining the life cycle of lytic and lysogenic bacteriophages. A video from the American Society of Microbiology linking CRISPR and bacteriophages. A review of genes "hitchhiking" in bacteriophages. An introduction to Phollow technology. An overview and discussion of the Phollow technology discussed in this podcast (paywalled).   A Phollow related publication also discussed during the podcast. The Wiles laboratory, where Dr. de Ora Ortiz and colleagues developed the Phollow technology. Dr. Travis Wiles' episode of #MattersMicrobial.  The Secor laboratory, where Dr. de Ora Ortiz currently works. Dr. de Ora Ortiz's LinkedIn profile. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

What do foot massage parties, otters, and AI robot tutors have in common? To find out, tune into our special end-of-year conversation featuring the hosts from TED Talks Daily, TED Radio Hour, TED Business, and TED Tech!Elise Hu, Manoush Zomorodi, Modupe Akinola and Sherrell Dorsey got together to share the biggest ideas dominating their industry and the lesser-known insights they wished garnered more attention. From pushing back against AI advances to sharing the TED Talks that inspired them, Elise, Manoush, Modupe, and Sherrell reflect on 2025 and look ahead to 2026.Conversations MentionedTED Radio HourRay Kurzweil, "Could AI extend your life indefinitely? Futurist Ray Kurzweil thinks so" LINK Victor Riparbelli, “Will AI avatars eventually teach our kids?” LINKPhilip Johns, “Singapore's otters are butting heads with their human neighbors. Can they coexist?” LINKRestoring trust in government, "Move fast...and fix democracy?" LINKTED TalksSitoyo Lopokoiyit in conversation with Jacqueline Novogratz "A story of moral imagination and bold entrepreneurship" LINKSarah Beery, "How AI is unearthing hidden scientific knowledge" LINKScott Loarie (of iNaturalist), "The surprising power of your nature photos" LINKDaniel Zavala-Araiza, "The best way to lower Earth's temperature — fast" LINKJennifer Pahlka, "Coding a better government" LINKPinky Cole (Slutty Vegan), "How I make vegan food sexy" LINKJason Huang, "The high-wire act of unlocking clean energy" LINKJennifer Doudna, "CRISPR's next advance is bigger than you think" LINKJonny Sun, "You are not alone in your loneliness" LINK Hosted on Acast. See acast.com/privacy for more information.

What do foot massage parties, otters, and AI robot tutors have in common? To find out, tune into our special end-of-year conversation featuring the hosts from TED Talks Daily, TED Radio Hour, TED Business, and TED Tech! Elise Hu, Manoush Zomorodi, Modupe Akinola and Sherrell Dorsey got together to share the biggest ideas dominating their industry and the lesser-known insights they wished garnered more attention. From pushing back against AI advances to sharing the TED Talks that inspired them, Elise, Manoush, Modupe, and Sherrell reflect on 2025 and look ahead to 2026.Conversations MentionedTED Radio HourRay Kurzweil, "Could AI extend your life indefinitely? Futurist Ray Kurzweil thinks so" Victor Riparbelli, “Will AI avatars eventually teach our kids?” Philip Johns, “Singapore's otters are butting heads with their human neighbors. Can they coexist?” Restoring trust in government, "Move fast...and fix democracy?" TED TalksSitoyo Lopokoiyit in conversation with Jacqueline Novogratz "A story of moral imagination and bold entrepreneurship" Sarah Beery, "How AI is unearthing hidden scientific knowledge" Scott Loarie (of iNaturalist), "The surprising power of your nature photos" Daniel Zavala-Araiza, "The best way to lower Earth's temperature — fast" Jennifer Pahlka, "Coding a better government" Pinky Cole (Slutty Vegan), "How I make vegan food sexy" Jason Huang, "The high-wire act of unlocking clean energy" Jennifer Doudna, "CRISPR's next advance is bigger than you think"Jonny Sun, "You are not alone in your loneliness" Hosted on Acast. See acast.com/privacy for more information.

What do foot massage parties, otters, and AI robot tutors have in common? To find out, tune into our special end-of-year conversation featuring the hosts from TED Talks Daily, TED Radio Hour, TED Business, and TED Tech!Elise Hu of TED Talks Daily hosted a conversation with Manoush Zomorodi, Modupe Akinola and Sherrell Dorsey, where they discussed the biggest ideas dominating their industry and the lesser-known insights they wished garnered more attention. From pushing back against AI advances to sharing the TED Talks that inspired them, Elise, Manoush, Modupe, and Sherrell reflect on 2025 and look ahead to 2026.Conversations MentionedTED Radio HourRay Kurzweil, "Could AI extend your life indefinitely? Futurist Ray Kurzweil thinks so" Victor Riparbelli, “Will AI avatars eventually teach our kids?” Philip Johns, “Singapore's otters are butting heads with their human neighbors. Can they coexist?” Restoring trust in government, "Move fast...and fix democracy?" TED TalksSitoyo Lopokoiyit in conversation with Jacqueline Novogratz "A story of moral imagination and bold entrepreneurship" Sarah Beery, "How AI is unearthing hidden scientific knowledge" Scott Loarie (of iNaturalist), "The surprising power of your nature photos" Daniel Zavala-Araiza, "The best way to lower Earth's temperature — fast" Jennifer Pahlka, "Coding a better government" Pinky Cole (Slutty Vegan), "How I make vegan food sexy" Jason Huang, "The high-wire act of unlocking clean energy" Jennifer Doudna, "CRISPR's next advance is bigger than you think"Jonny Sun, "You are not alone in your loneliness" Hosted on Acast. See acast.com/privacy for more information.

00:46 The gifts that sparked a love of scienceNature put a call out for readers to tell us about memorable presents that first got them interested in science, or mementos of their life in research. These include telescopes, yeast-themed wedding rings, and... cows' eyes.Nature: The gift that shaped my career in science08:12 “I am the Very Model of a Miniature Tyrannosaur”In the first of our annual festive songs celebrating the science of the past year, we tell the story of a diminutive dinosaur that turned out to be its own species.Nature Podcast: Meet the ‘Wee-rex'. Tiny tyrannosaur is its own speciesNature Video: Hotly debated dinosaur is not a tiny T. rex after all11:43 A very scientific quizAn all-star cast competes for the glory or being the winner of the Nature Podcast's 2025 festive quiz.Nature: Meet the ‘Wee-rex'. Tiny tyrannosaur is its own speciesNature: This company claimed to ‘de-extinct' dire wolves. Then the fighting startedNature Podcast: 3D-printed fake wasps help explain bad animal mimicryNature Video: ‘Aqua tweezers' manipulate particles with water wavesNature Podcast: Sapphire anvils squeeze metals atomically-thinNature Video: Vesuvius volcano turned this brain to glassNature Podcast: Ancient viral DNA helps human embryos developNature Video: Magnetic fibres give this robot a soft gripNature: These contact lenses give people infrared vision — even with their eyes shutNature Video: Is this really the world's largest mirror? Researchers put it to the testNature Podcast: World's tiniest pacemaker could revolutionize heart surgeryNature Podcast: Earth's deepest ecosystem discovered six miles below the seaNature Podcast: Nature goes inside the world's largest ‘mosquito factory' — here's the buzzNature Podcast: Apocalypse then: how cataclysms shaped human societiesNature Podcast: Honey, I ate the kids: how hunger and hormones make mice aggressive25:21 “Hard the Hydrogel is Stuck”Our second festive song is an ode to a rubber duck that was stuck to a rock, thanks to a newly designed, super-adhesive hydrogel.Nature Podcast: Underwater glue shows its sticking power in rubber duck testNature Video: Why did researchers stick a duck to a rock? To show off their super glue28:42 Nature's 10Each year, Nature's 10 highlights some of the people who have helped shape science over the past 12 months. We hear about a few of the people who made the 2025 list, including: a civil servant who stood up for evidence-based public-health policy; the science sleuth who revealed a retraction crisis at Indian universities; and the baby whose life was saved by the first personalized CRISPR therapy.Nature: Nature's 10Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. Hosted on Acast. See acast.com/privacy for more information.

In this episode of The Brainstorm, we delve into the groundbreaking advancements in gene editing, focusing on its potential to transform healthcare. We explore the shift from treating rare diseases to tackling common killers like cardiovascular disease, and discover how CRISPR technology is paving the way for a new era in medical treatment.If you know ARK, then you probably know about our long-term research projections, like estimating where we will be 5-10 years from now! But just because we are long-term investors, doesn't mean we don't have strong views and opinions on breaking news. In fact, we discuss and debate this every day. So now we're sharing some of these internal discussions with you in our new video series, “The Brainstorm”, a co-production from ARK and Wolf.financial, and sponsored by Public. Tune in every week as we react to the latest in innovation. Here and there we'll be joined by special guests, but ultimately this is our chance to join the conversation and share ARK's quick takes on what's going on in tech today.Key Points From This Episode:CRISPR-based gene editing is moving from treating rare diseases to addressing common conditions like cardiovascular disease.The transition from ex vivo to in vivo gene editing could simplify treatment processes significantly.Lipid nanoparticle delivery is a key advancement enabling in vivo gene editing.The potential market for in vivo gene editing treatments is vast, with significant implications for healthcare costs and patient outcomes.To learn more about WOLF: https://wolf.financialTo learn more about Public: https://public.com/Relevant Links:https://www.ark-invest.com/newsletters/issue-491